Merck Company Profile

✉ Email this page to a colleague

MERCK has ninety-two approved drugs.

There are twenty-seven US patents protecting MERCK drugs.

There are seven hundred and forty-four patent family members on MERCK drugs in sixty-three countries and one hundred and eighty-two supplementary protection certificates in nineteen countries.

International Patents:	744
US Patents:	27
Tradenames:	77
Ingredients:	70
NDAs:	92
Patent Litigation for Merck:	See patent lawsuits for Merck
PTAB Cases with Merck as patent owner:	See PTAB cases with Merck as patent owner

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	DECADRON	dexamethasone sodium phosphate	CREAM;TOPICAL	011983-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Merck Sharp Dohme	VERQUVO	vericiguat	TABLET;ORAL	214377-002	Jan 19, 2021		RX	Yes	No	8,921,377	⤷ Subscribe				⤷ Subscribe
Merck	HYDROCORTONE	hydrocortisone	TABLET;ORAL	008506-007	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Merck	HYDROCORTONE	hydrocortisone acetate	INJECTABLE;INJECTION	008228-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	DUTREBIS	lamivudine; raltegravir potassium	TABLET;ORAL	206510-001	Feb 6, 2015	7,435,734*PED	⤷ Subscribe
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	6,524,570*PED	⤷ Subscribe
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-002	Oct 16, 2006	7,078,381	⤷ Subscribe
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	7,459,428	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2011-02-28
➤ Subscribe	Injection	18 mg/mL, 16.7 mL vials	➤ Subscribe	2015-11-24
➤ Subscribe	Orally Disintegrating Tablets	2.5 mg and 5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-19
➤ Subscribe	Capsule	40 mg, 80 mg and 125 mg	➤ Subscribe	2008-11-03
➤ Subscribe	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg	➤ Subscribe	2012-11-06
➤ Subscribe	Injection	150 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	For Injection	50 mg/vial and 70 mg/vial	➤ Subscribe	2009-06-26
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Capsules	140 mg and 180 mg	➤ Subscribe	2008-03-24
➤ Subscribe	Delayed-release Tablets	100 mg	➤ Subscribe	2014-06-16
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	25 mg, 50 mg and 100 mg	➤ Subscribe	2010-10-18
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-25
➤ Subscribe	Injection	115 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	for Oral Suspension	125 mg/Kit	➤ Subscribe	2016-11-23
➤ Subscribe	Oral Solution	70 mg/75 mL	➤ Subscribe	2007-09-07

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
China	104321059	⤷ Subscribe
Eurasian Patent Organization	007332	⤷ Subscribe
Slovenia	3417851	⤷ Subscribe
Hong Kong	1092463	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	SPC/GB02/002	United Kingdom	⤷ Subscribe	A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
1412357	42/2007	Austria	⤷ Subscribe	PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001-018 (MITTEILUNG) 20070323
1412357	PA2008013	Lithuania	⤷ Subscribe	PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
1385870	CA 2011 00036	Denmark	⤷ Subscribe	PRODUCT NAME: BOCEPREVIR ELLER EN ENANTIOMER, EN STEREOISOMER, EN ROTAMER, EN TAUTOMER ELLER ET RACEMAT AF DENNE FORBINDELSE, ELLER FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT AF DENNE FORBINDEL
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.